Amedisys (NAS: AMED) is expected to report Q3 earnings on Nov. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Amedisys's revenues will grow 1.4% and EPS will shrink -25.0%.
The average estimate for revenue is $380.0 million. On the bottom line, the average EPS estimate is $0.27.
Last quarter, Amedisys reported revenue of $378.5 million. GAAP reported sales were 2.7% higher than the prior-year quarter's $368.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.27. GAAP EPS of $0.26 for Q2 were 65% lower than the prior-year quarter's $0.75 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 43.9%, 470 basis points worse than the prior-year quarter. Operating margin was 4.1%, 680 basis points worse than the prior-year quarter. Net margin was 2.1%, 380 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.51 billion. The average EPS estimate is $1.01.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 815 members out of 907 rating the stock outperform, and 92 members rating it underperform. Among 214 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 183 give Amedisys a green thumbs-up, and 31 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.61.
Add Amedisys to My Watchlist.
The article What to Expect from Amedisys originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Amedisys. Motley Fool newsletter services recommend Amedisys. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy